Monitor partnership announcements or financing events as the primary catalyst. The cash runway into Q4 2026 provides a timeline for deal-making; failure to secure funding before then would risk going concern. The Phase 2b DKD study initiation is the key value inflection point.
Price Chart
Executive Summary
Vivoryon reported Q1 2026 results with no revenue, a net loss of EUR 1.8M (improved from EUR 2.5M a year ago), and cash of EUR 4.0M, sufficient into Q4 2026. The company highlighted compelling kidney function data from Phase 2 studies of varoglutamstat and ongoing partnership discussions, but all future development is contingent on additional funding.
Key Facts
- No revenue generated in Q1 2026.
- Net loss of EUR 1.8 million, improved from EUR 2.5 million in Q1 2025.
- Cash and cash equivalents of EUR 4.0 million as of March 31, 2026.
- Cash runway guidance: sufficient into Q4 2026, subject to no unforeseen circumstances.
- Phase 2b DKD study initiation and all future studies subject to additional funding/partnership.
- Active due diligence processes with multiple potential partners.
- Compelling kidney function data from VIVIAD and VIVA-MIND Phase 2 studies presented at WCN 2026.
Financial Impact
Net loss improved by EUR 0.7 million year-over-year; cash burn rate reduced. No revenue.
Risk Factors
- Going concern risk if additional funding not secured before cash depletion in Q4 2026.
- Dependence on partnership or financing to advance Phase 2b study.
- No revenue and continued operating losses.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310182 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | Press Release | — | awaiting T+20 | — | — |
Jul 22, 2026 13w ago | Press Release | — | awaiting T+20 | — | — |
Jun 11, 2026 19w ago | Press Release | — | awaiting T+20 | — | — |
Jun 8, 2026 20w ago | Press Release | — | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 15, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Apr 9, 2026 28w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers